Compare FTHY & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHY | CGC |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 401.0M |
| IPO Year | N/A | 2023 |
| Metric | FTHY | CGC |
|---|---|---|
| Price | $13.55 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 80.2K | ★ 3.5M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.20 | $0.84 |
| 52 Week High | $14.86 | $2.38 |
| Indicator | FTHY | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 33.83 |
| Support Level | $13.40 | $0.84 |
| Resistance Level | $13.78 | $1.23 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 48.08 | 16.45 |
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.